Precigen (Precigen) EBIT

: $-95.89 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Precigen's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-33.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-95.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Precigen's annualized ROC % for the quarter that ended in Dec. 2023 was -93.43%. Precigen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -943.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Precigen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -33.33%.

Precigen EBIT Historical Data

The historical data trend for Precigen's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-86.32

-85.46

-92.21

-73.19

-95.89

Precigen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-21.53	-22.47	-20.25	-19.80	-33.38

Competitive Comparison

For the Biotechnology subindustry, Precigen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precigen EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Precigen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Precigen's EV-to-EBIT falls into.

Precigen EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-95.89 Mil.

Precigen (NAS:PGEN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Precigen's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-93.556 * ( 1 - 0.99% )	/	( (106.03	+	92.249)	/ 2 )
=	-92.6297956	/	99.1395
=	-93.43 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	190.688	-	24.545	-	( 73.755	-	max(0, 32.875	-	92.988	+	73.755	))
=	106.03

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	151.043	-	13.024	-	( 62.855	-	max(0, 22.985	-	68.755	+	62.855	))
=	92.249

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Precigen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-133.524	/	( ( (14.179 + max(-25.559, 0))	+	(14.129 + max(-16.556, 0)) )	/	2 )
=	-133.524	/	( ( 14.179	+	14.129 )	/	2 )
=	-133.524	/	14.154
=	-943.37 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.988	+	0	+	5.128)	-	(24.545	+	0.509	+	6.621)
=	-25.559

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.902	+	0	+	4.325)	-	(13.024	+	0.509	+	8.25)
=	-16.556

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Precigen's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-95.894	/	287.750
	=	-33.33 %

Precigen EBIT Related Terms

Thank you for viewing the detailed overview of Precigen's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen (Precigen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

I5X:Germany I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Executives

Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk	director, 10 percent owner, officer: Chief Executive Officer	1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari	director, officer: President and CEO	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah	officer: Chief Operating Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian	officer: Chief Financial Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez	officer: SVP, IP Affairs	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr	officer: Chief Legal Officer	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro	director	155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez	director	C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley	director	9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a.	10 percent owner	ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170